WallStreetZenWallStreetZen

NASDAQ: TSHA
Taysha Gene Therapies Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

TSHA past revenue growth

How has TSHA's revenue growth performed historically?
Company
96.39%
Industry
84.49%
Market
19.29%
TSHA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TSHA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TSHA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TSHA earnings and revenue history

Current Revenue
$14.2M
Current Earnings
-$118.0M
Current Profit Margin
-833.6%

TSHA Return on Equity

Current Company
-1,109.1%
Current Industry
16.9%
Current Market
28.2%
TSHA's Return on Equity (-1,109.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TSHA announces earnings.

TSHA Return on Assets

Current Company
-78.3%
Current Industry
3.2%
TSHA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TSHA Return on Capital Employed

Current Company
-99.99%
Current Industry
-42.5%
TSHA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TSHA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TSHA$14.16M-$111.78M-$118.01M+96.39%N/A
PROK$0.00-$26.39M-$35.30MN/AN/A
TNGX$37.23M-$105.36M-$111.65M+144.07%N/A
OLMA$0.00-$97.72M-$99.34MN/AN/A
MESO$7.25MN/A-$73.06M-14.93%N/A
View Top Biotech Stocks

Taysha Gene Therapies Earnings & Revenue FAQ

What were TSHA's earnings last quarter?

On Invalid Date, Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 2024 earnings per share (EPS) of -$0.10, up 64.29% year over year. Total Taysha Gene Therapies earnings for the quarter were -$24.06 million. In the same quarter last year, Taysha Gene Therapies's earnings per share (EPS) was -$0.28.

If you're new to stock investing, here's how to buy Taysha Gene Therapies stock.

What was TSHA's earnings growth in the past year?

As of Q2 2024, Taysha Gene Therapies's earnings has grown year over year. Taysha Gene Therapies's earnings in the past year totalled -$118.01 million.

What was TSHA's revenue last quarter?

On Invalid Date, Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 2024 revenue of $3.41 million up 27.52% year over year. In the same quarter last year, Taysha Gene Therapies's revenue was $4.71 million.

What was TSHA's revenue growth in the past year?

As of Q2 2024, Taysha Gene Therapies's revenue has grown 96.39% year over year. This is 11.9 percentage points higher than the US Biotechnology industry revenue growth rate of 84.49%. Taysha Gene Therapies's revenue in the past year totalled $14.16 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.